Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*

/PRNewswire/ -- Juniper Biologics Pte Ltd, a science-led healthcare company focused on researching, developing and commercializing novel therapies, and Helsinn...

Related Keywords

Qatar ,Australia ,Taiwan ,United States ,China ,Brunei ,Mauritius ,Tanzania ,Angola ,Coted Ivoire ,Sri Lanka ,Woman ,Bahrain ,New Zealand ,India ,Nigeria ,Egypt ,Cambodia ,Morocco ,Zimbabwe ,Kuwait ,Nepal ,Lugano ,Ticino ,Switzerland ,Libya ,Ireland ,South Korea ,Malaysia ,Japan ,Philippines ,Seychelles ,Algeria ,Lebanon ,Vietnam ,Republic Of ,Laos ,South Africa ,Indonesia ,United Arab Emirates ,Canada ,Jordan ,Pakistan ,Kenya ,Thailand ,Singapore ,Saudi Arabia ,Ivory Coast ,Raman Singh ,Giorgio Calderari ,Gastroenterol Hepatol ,European Network For The Study Of Cholangiocarcinoma ,Linkedin ,Twitter ,Prnewswire Juniper Biologics Pte Ltd ,Drug Administration ,Helsinn Birex Pharmaceuticals Ltd ,Therapeutics Goods Association ,Helsinn Group ,Health Canada ,Sylvan Group ,Biologics Pte Ltd ,Southeast Asia ,Middle East ,Therapeutics Goods Association Approved ,Juniper Biologics ,Fully Integrated Targeted Therapy ,Important Safety Information ,Prescribing Information ,Full Prescribing Information ,Helsinn Birex Pharmaceuticals ,Orphan Diseases ,European Network ,Nat Rev Gastroenterol Hepatol ,Rev Gastroenterol Hepatol ,